We identified six of such proteins, listed in Table 2, as potential targets for subtype‐specific therapies: aromatic‐L‐amino‐acid decarboxylase (DDC, overexpressed in SCLC‐A), ephrin type‐A receptor 2 (EPHA2), integrin alpha‐V and beta‐1 (ITGAV, ITGB1, overexpressed in SCLC‐Y), histone deacetylase 1 (overexpressed in SCLC‐A/N/P vs. SCLC‐Y), and mast/stem cell growth factor receptor Kit (KIT, overexpressed in SCLC‐P). This evidence concerns the gene KIT and small cell lung carcinoma.